LOBEF News and Press, Lobe Sciences Ltd From 09/14/23

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase agreeme...

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an Inte...

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to date Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative m...

2023-06-07 07:29:39 ET Biopharmaceutical company Lobe Sciences ( OTCQB:LOBEF ) said on Wednesday that Baxter Phillips III has been appointed to the newly created position of COO, effective immediately. The position was created to provide additional executive leadership. Additi...

Phillips also named President of Altemia & Co., a Lobe Sciences Company Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxte...

2023-05-17 09:15:50 ET Lobe Sciences ( OTCQB:LOBEF ) has entered into a commercial distribution agreement with Pentec Health, Inc. for the supply and distribution of Altemia. Altemia is Lobe's proprietary formulation of emulsified docosahexaenoic acid ethyl ester (DHA) concentrati...

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical Food Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the " Company "), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an u...

2023-04-18 09:55:55 ET Lobe Sciences ( OTCQB:LOBEF ) to acquire a 100% interest in Altemia & Company, which includes all assets, know-how, intellectual property and commercial inventory of the seller to manage patients suffering from Sickle Cell Disease. The seller has no ...

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an Inte...